PRAX vs. SAGE, ICPT, TVTX, CMPS, MGNX, AGIO, MLTX, DYN, RNA, and RYTM
Should you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Sage Therapeutics (SAGE), Intercept Pharmaceuticals (ICPT), Travere Therapeutics (TVTX), COMPASS Pathways (CMPS), MacroGenics (MGNX), Agios Pharmaceuticals (AGIO), MoonLake Immunotherapeutics (MLTX), Dyne Therapeutics (DYN), Avidity Biosciences (RNA), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "medical" sector.
Praxis Precision Medicines (NASDAQ:PRAX) and Sage Therapeutics (NASDAQ:SAGE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Sage Therapeutics has a net margin of -552.52% compared to Praxis Precision Medicines' net margin of -5,711.85%. Sage Therapeutics' return on equity of -56.81% beat Praxis Precision Medicines' return on equity.
Praxis Precision Medicines currently has a consensus price target of $105.80, suggesting a potential upside of 165.76%. Sage Therapeutics has a consensus price target of $35.05, suggesting a potential upside of 225.14%. Given Sage Therapeutics' higher possible upside, analysts plainly believe Sage Therapeutics is more favorable than Praxis Precision Medicines.
Praxis Precision Medicines has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
In the previous week, Sage Therapeutics had 4 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 9 mentions for Sage Therapeutics and 5 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.76 beat Sage Therapeutics' score of 0.31 indicating that Praxis Precision Medicines is being referred to more favorably in the media.
Praxis Precision Medicines has higher earnings, but lower revenue than Sage Therapeutics. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.
67.8% of Praxis Precision Medicines shares are owned by institutional investors. Comparatively, 99.2% of Sage Therapeutics shares are owned by institutional investors. 2.7% of Praxis Precision Medicines shares are owned by insiders. Comparatively, 5.5% of Sage Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Sage Therapeutics received 600 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. Likewise, 67.60% of users gave Sage Therapeutics an outperform vote while only 63.41% of users gave Praxis Precision Medicines an outperform vote.
Summary
Sage Therapeutics beats Praxis Precision Medicines on 12 of the 18 factors compared between the two stocks.
Get Praxis Precision Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Praxis Precision Medicines Competitors List
Related Companies and Tools
